885271-73-8 Usage
Uses
Used in Organic Synthesis:
TERT-BUTYL 3,7-DIAZABICYCLO[4.2.0]OCTANE-7-CARBOXYLATE is used as a reagent in organic synthesis for its ability to facilitate a variety of chemical reactions. Its unique structure allows it to participate in reactions that lead to the formation of new compounds, making it a valuable tool in the synthesis of complex organic molecules.
Used in Catalysis:
In the field of catalysis, TERT-BUTYL 3,7-DIAZABICYCLO[4.2.0]OCTANE-7-CARBOXYLATE is employed as a catalyst to accelerate chemical reactions. Its presence lowers the activation energy required for reactions to proceed, thereby increasing the reaction rate and improving the overall efficiency of the process.
Used in Pharmaceutical Industry:
TERT-BUTYL 3,7-DIAZABICYCLO[4.2.0]OCTANE-7-CARBOXYLATE is utilized in the pharmaceutical industry for the production of certain drugs. Its unique chemical properties make it suitable for use in the synthesis of medicinal compounds, contributing to the development of new and effective pharmaceuticals.
Used in Chemical Research:
In the realm of chemical research, TERT-BUTYL 3,7-DIAZABICYCLO[4.2.0]OCTANE-7-CARBOXYLATE is used as a subject of study to explore its properties and potential applications. Researchers investigate its reactivity, stability, and interactions with other compounds to gain insights into its behavior and to discover new uses for this versatile chemical.
Check Digit Verification of cas no
The CAS Registry Mumber 885271-73-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,5,2,7 and 1 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 885271-73:
(8*8)+(7*8)+(6*5)+(5*2)+(4*7)+(3*1)+(2*7)+(1*3)=208
208 % 10 = 8
So 885271-73-8 is a valid CAS Registry Number.
885271-73-8Relevant articles and documents
HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS
-
, (2008/12/07)
A compound of Formula 1: A-C(O)-Cy, wherein A is a diazabicyclic core, containing 7, 8, or 9 ring atoms, and selected from the following: 2,6-diazabicyclo[3.2.0]heptane; 3,6-diazabicyclo[3.ZO]heptane; 2,7-diazabicyclo[4.2.0]octane; 3,7-diazabicyclo[4.2.0]octane; 3,8-diazabicyclo[4.2.0]octane; 2,7-diazabicyclo[3.3.0]octane; 2,7-diazbicyclo[4.3.0]nonane; 2,8-diazbicyclo[4.3.0]nonane; 3,7-diazabicyclo[4.3.0]nonane; 3,8-diazabicyclo[4.3.0]nonane; 3,9-diazabicyclo[4.3.0]nonane; 2,6-diazabicyclo[3.2.1 ]octane; 3,6-diazabicyclo[3.2.1]octane; wherein the diazabicycle is attached as a radical to the depicted carbonyl via either one of the two ring nitrogen atoms, such that the carbonyl forms an amide bond with the ring nitrogen; Cy is a heteroaryi group; The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the α402 subtype in the central nervous system (CNS). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly CNS disorders. The compounds are believed to: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects, and (iii) when employed in effective amounts, not result in appreciable adverse side effects, namely side effects such as significant Increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle.
